Evidence map›Paper›PMID 36796336›Full record

ArticleDermatology (Basel, Switzerland)2023

Clinical Characteristics and Outcomes of Generalized Pustular Psoriasis Flares.

Siew Eng Choon, Mark G Lebwohl, Hamida Turki, Min Zheng, A David Burden, Ling Li, Manuel Quaresma, Christian Thoma, Hervé Bachelez

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?Clinical, cosmetic and investigational dermatology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 7 countries.

Siew Eng ChoonDepartment of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Johor Bahru, Malaysia.
Mark G LebwohlIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Hamida TurkiDepartment of Dermatology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia.
Min ZhengDepartment of Dermatology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
A David BurdenInstitute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Ling LiBoehringer Ingelheim (China), Investment Co., Ltd., Shanghai, China.
Manuel QuaresmaBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Christian ThomaBoehringer Ingelheim International GmbH, Biberach, Germany.
Hervé BachelezService de Dermatologie, Assistance Publique - Hôpitaux de Paris Hôpital Saint-Louis, and INSERM Unité 1163, Imagine Institute of Genetic Diseases, Université Paris Cité, Paris, France.
Boehringer Ingelheim (Germany) · DEBoehringer Ingelheim (China) · CNIcahn School of Medicine at Mount Sinai · USInserm · FRMonash University Malaysia · MYSecond Affiliated Hospital of Zhejiang University · CNUniversity of Glasgow · GBUniversity of Sfax · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGeneralized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options.

objectiveThe aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial.

methodsInvestigators collected retrospective medical data characterizing patients' GPP flares prior to clinical trial enrollment. Data on overall historical flares were collected, as well as information on patients' typical, most severe, and longest past flares. This included data on systemic symptoms, flare duration, treatment, hospitalization, and time to clearance of skin lesions.

resultsIn this cohort (N = 53), patients with GPP experienced a mean of 3.4 flares per year. Flares were painful, associated with systemic symptoms, and often triggered by stress, infections, or treatment withdrawal. Resolution of flares was longer than 3 weeks in 57.1%, 71.0%, and 85.7% of documented (or identified) typical, most severe, and longest flares, respectively. GPP flares led to patient hospitalization in 35.1%, 74.2%, and 64.3% of patients for their typical, most severe, and longest flares, respectively. For the majority of patients, pustules took up to 2 weeks to clear for a typical flare and 3-8 weeks to clear for the most severe and longest flares.

conclusionOur findings highlight that current treatment options are slow to control GPP flares and provide context for assessing the efficacy of new therapeutic strategies in patients with a GPP flare.

Indexed as

PsoriasisHumansRetrospective StudiesClinical researchClinical trialGeneralized pustular psoriasisPsoriasis

Identifiers

PMID36796336
PMCPMC10233699
OpenAlexW4321018589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.